Pharmafile Logo
Pharmafocus logo
Advanced Search

keytruda

Showing 15 posts of 134 posts found.

merckincweb1

MSD’s Keytruda boosts overall survival by 31% in advanced oesophageal cancer

January 16, 2019
Research and Development Cancer, MSD, keytruda, oesophageal cancer, pharma

MSD has unveiled new Phase 3 data for its blockbuster anti-PD-1 immunotherapy Keytruda (pembrolizumab), showing that the drug succeeded in …

News

Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer

November 22, 2018
Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma

MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …

News

MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund

November 19, 2018
Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …

News
merckentranceweb

MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer

November 15, 2018
Research and Development Cancer, MSD, PD-L1, keytruda, pharma

MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …

News
msd

MSD’s Keytruda chalks up FDA approval in liver cancer

November 12, 2018
Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …

News
merckincweb2

MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

November 1, 2018
Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …

News
merckincweb2

First-line Keytruda shows better overall survival in head & neck cancer

October 23, 2018
Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma

MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …

News
merckincweb

MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer

October 19, 2018
Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma

MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …

News
merckwindow_web

MSD to launch Keytruda at half US list price in China

September 20, 2018
Business Services, Sales and Marketing BMS, China, MSD, global, keytruda, markets, pricing

US pharma giant MSD will offer cutting edge cancer treatment Keytruda to Chinese patients at half the price at what …

News
merckentranceweb

Keytruda scores ground-breaking European approval in lung cancer subgroup

September 10, 2018
Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma

Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …

News

NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer

June 5, 2018
Research and Development MSD, Merck, NHS, NICE, keytruda, pharma

UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …

News
merck_and_co

MSD’s Keytruda scores impressive first-line lung cancer data

May 24, 2018
Research and Development, Sales and Marketing MSD, biotech, drugs, keytruda, pharma, pharmaceutical

MSD Keytruda has enjoyed the most success of the PD-1/L1 therapies in clinical trials recently and it’s rapidly cementing its …

News
pharmafocus_may_2018_cover

The May 2018 issue of Pharmafocus is now live!

April 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax

Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

News
merckwindow_web

Keytruda success continues, beating Opdivo in lung cancer survival

April 17, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026